Session Information

  • WCLC 2022

    2022 World Conference on Lung Cancer

    As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.

    Presentation Date(s):  
    • August 6 - 9, 2022
    • Total Presentations: 2015

    All times listed are in Vienna, Austria Time, CEST (UTC+2:00)

    PL - Plenary
    IBS - Interactive Breakfast Session (in-person attendees only)
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    P - Posters
    EP - ePosters
    WS - Workshops
    LA – Lectureship Awards
    IS - Industry Symposium

Filter Results:

Show Only CME Accredited Sessions

  • +

    EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      EP08.02-118 - TRUST-II: A Global Phase II Study for Taletrectinib inROS1fusion Positive Lung Cancer and Other Solid Tumors

      Presenter: Misako Nagasaka

      • Abstract

      Loading...

  • +

    P1.15 - Metastatic Non-small Cell Lung Cancer - Immunotherapy

    • 17:00 - 19:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: Regular Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
    • +

      P1.15-11 - Durvalumab + Olaparib vs Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: Outcomes from the Phase 2 ORION Study

      Presenter: Myung-Ju Ahn

      • Abstract

      Loading...

  • +

    MA06 - Resectable and Unresectable Locally Advanced Lung Cancer

    • 12:15 - 13:15
    • 8/08/2022
    • Location: Lehar 1
    • Not for CME Credit
    • Type: Mini Oral
    • Track: Locally Advanced Non-small Cell Lung Cancer
    • +

      MA06.04 - Phase II Study of Durvalumab Plus Concurrent Radiotherapy in Unresectable Locally Advanced NSCLC: DOLPHIN Study (WJOG11619L)

      12:22 - 12:27  |  Presenter: Motoko Tachihara

      • Abstract

      Loading...